goldman sachs moderna

Moderna slips

Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Business Insider · 1d

Moderna downgraded to Neutral from Buy at Goldman Sachs

Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance

Seeking Alpha on MSN · 1d

Moderna slips as Goldman Sachs downgrades on revenue outlook

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook. Read more here.

Moderna Stock Is Sliding Wednesday: Here's Why

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

14hon MSN

Why Moderna (MRNA) Crashed on Wednesday?

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Wall Street Journal9d

Goldman Sachs Promotes Its Next Generation of Leaders

Goldman Sachs GS-0.41%decrease; red down pointing triangle announced a number of promotions in its global banking and ...

Moderna Hold Recommendation Amid Reduced Revenue Projections and Price Target

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

Yahoo Finance2d

Moderna, Inc. (MRNA)

mRNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman Cut Its Rating on MRNA Earlier this month, Moderna reduced its ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results